FDA Panel Backs 6 Peptides for Compounding: What's Next
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
An FDA advisory panel voted in late July to recommend six of seven peptides for the list of ingredients that licensed pharmacies may use in compounding (RAPS). The votes were close, they went against the FDA's own scientists, and they do not make anything legal to compound yet (NPR). The decision now sits with the FDA, and the formal process that follows usually takes a year or more.
Who This Helps
This is for anyone following peptide access, anyone who has seen these ingredients sold online, and anyone who wants to know whether licensed pharmacies will be able to make them soon. It is also for people on a GLP-1 who want to know whether this touches their medication.
What the Panel Voted
The Pharmacy Compounding Advisory Committee met on July 23 and 24 to weigh seven peptides for the 503A Bulks List, the set of bulk ingredients that licensed 503A pharmacies are allowed to compound (FDA). Six earned a favorable recommendation and one did not (RAPS):
- Recommended on day one: BPC-157, KPV, and TB-500, each by 8 to 6 with one abstention, and MOTS-c by 7 to 5 with two abstentions.
- Recommended on day two: Semax by 8 to 5, and Epitalon by 7 to 4.
- Not recommended: emideltide, also called DSIP, which failed on a 6 to 7 vote.
What Each Peptide Was Proposed to Treat
Every peptide came to the committee with a specific proposed use, and those uses are narrower than what you often see advertised. These are the uses submitted for review, not approved uses (Drug Topics):
- BPC-157: proposed for ulcerative colitis, a form of inflammatory bowel disease.
- KPV: proposed for wound healing and inflammatory conditions.
- TB-500: proposed for wound healing.
- MOTS-c: proposed for obesity and osteoporosis, a condition of weakened bones.
- Semax: proposed for cerebral ischemia, meaning reduced blood flow to the brain, plus migraine and trigeminal neuralgia, a facial nerve pain condition (RAPS).
- Epitalon: proposed for insomnia.
- Emideltide (DSIP): proposed for insomnia, narcotic dependence, and opioid withdrawal. This is the one the committee did not recommend.
None of these peptides is an FDA-approved drug, and a favorable vote is not a finding that any of them work for the use listed. FDA reviewers concluded the evidence fell short across all seven, with no human clinical trial data at all for KPV, TB-500, and MOTS-c, and small or poorly controlled studies behind BPC-157, emideltide, and Semax (Orrick).
The reviewed use also often differs from how a peptide is sold online. BPC-157 is widely promoted for tendon and sports injury recovery, for example, while the use the committee actually weighed was ulcerative colitis. A recommendation covers the specific use that was nominated, not every claim attached to the ingredient.
What this means for you: if you see a peptide advertised for a purpose that is not on this list, that purpose was not what the FDA reviewed. Ask a licensed clinician what evidence exists for your specific situation.
Why This Vote Was Unusual
The panel sided against the agency's own reviewers. FDA career scientists had recommended not adding any of the seven, saying the evidence on safety and effectiveness was thin, with no human clinical data at all for several of them (NPR).
The committee's makeup also drew attention, since several newly appointed members run practices that administer peptides, and reporting noted those members voted in favor (NBC News). That does not invalidate the votes, and it is part of why the recommendations are being read as advisory rather than decisive (Science).
What This Does Not Change Right Now
A recommendation is not a rule. The committee advises the FDA, and a peptide becomes eligible for compounding only when the agency actually adds it to the 503A Bulks List through formal rulemaking (FDA).
What this means for you: nothing on the market changed the day of the vote. A favorable vote is not FDA approval, and it is not a finding that these peptides are safe or effective.
What Happens Next
The path from here runs through several steps, and none of them are quick (Orrick):
- The FDA decides whether to accept the committee's recommendations, and it is not required to follow them.
- If it moves ahead, the agency publishes a proposed rule and opens a public comment period, typically 60 to 90 days.
- The FDA reviews comments and issues a final rule, which is the step that actually adds a substance to the list.
- Start to finish, this process commonly takes about 12 to 24 months, though the agency could use interim enforcement policies as a stopgap.
A second committee meeting is expected before the end of February 2027 to consider five more peptides, including LL-37, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF.
So How Likely Is Compounding?
More likely than it was a month ago, and still far from settled. The recommendations give the FDA cover to move, and the agency has already signaled openness by moving a group of peptides off its restricted category earlier this year (FDA). Our earlier post on the 2026 FDA peptide reclassification covers that shift.
Pushing the other way, the agency's reviewers found the evidence lacking, the votes were narrow, and rulemaking invites objections that can slow or reshape the outcome. A fair read is that some of these peptides have a real chance of becoming compoundable, on a timeline measured in quarters rather than weeks, and that the FDA could still decline any of them.
Does This Affect Your GLP-1?
No. These seven are wellness and recovery peptides, not the GLP-1 medicines used for weight loss and diabetes, and they follow a separate regulatory track (FDA). However the FDA rules, your GLP-1 prescription and how it is compounded are not changed by this vote.
What to Do While You Wait
The gap between a favorable vote and a final rule is exactly when marketing tends to get ahead of the law, so a little skepticism goes a long way.
- Treat claims that a peptide is now FDA approved or newly legal as a red flag, since a committee recommendation is neither (FDA).
- Ask any pharmacy or clinic what its legal basis is for making a specific peptide today, rather than what a panel recommended.
- Stick with licensed 503A pharmacies or FDA-registered 503B outsourcing facilities, which operate under real oversight, and see our explainer on 503A and 503B pharmacies for the difference.
- Keep away from sellers marketing research-only products for personal use, which our guide to grey-market peptides walks through.
What this means for you: watch the rulemaking, not the headlines. If you want to compare providers, including compounding options and the pharmacies they work with, you can use the GLP Winner provider survey.
Final Takeaway
An FDA advisory panel backed six of seven peptides for the compounding list, a real shift after years of restriction. The votes were narrow and went against the agency's own scientists.
None of it is law yet. The FDA still has to accept the advice, propose a rule, take public comment, and finalize it, which usually runs a year or more.
If you take a GLP-1, this does not touch your prescription. It is a separate track with separate rules.
The honest status is promising but unfinished. Follow the FDA's next move, and be wary of anyone selling certainty before the rule exists.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Which peptides did the FDA panel recommend for compounding?
The committee gave favorable recommendations to BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. It voted against emideltide, also known as DSIP, in a close 6 to 7 vote.
What are these peptides supposed to treat?
The proposed uses submitted for review were ulcerative colitis for BPC-157, wound healing and inflammation for KPV, wound healing for TB-500, obesity and osteoporosis for MOTS-c, cerebral ischemia and migraine and trigeminal neuralgia for Semax, and insomnia for Epitalon. None of these are FDA-approved uses.
Does this mean peptides are legal to compound now?
No. The vote is a non-binding recommendation to the FDA. A peptide can be compounded by a licensed pharmacy only after the FDA adds it to the 503A Bulks List through formal rulemaking, which has not happened.
How long until pharmacies can compound these peptides?
If the FDA moves ahead, it must propose a rule, take public comment for roughly 60 to 90 days, and issue a final rule. That process commonly takes about 12 to 24 months, and the agency could still decline.
Does this vote affect my GLP-1 medication?
No. These are wellness and recovery peptides that follow a different regulatory path from GLP-1 medicines like semaglutide and tirzepatide. The vote does not change how your GLP-1 is prescribed or compounded.
Sources
Keep Reading
Some peptides are FDA-approved medicines and some "research" peptides are risky. A plain-language guide to telling safe sources from unsafe ones.
The FDA moved 12 peptides off its restricted list and reviews 7 in July 2026. See what it could mean for compounding, your GLP-1, and peptide safety.
An FDA panel meets July 23-24 to weigh whether 7 peptides can be compounded. See which peptides, what the FDA recommends, and what it means.
Categories
Curated by
